Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Thrombospondin-2 is up-regulated by TGFβ2 and increases fibronectin expression in human trabecular meshwork cells.

Kennedy SM, Sheridan C, Kearns VR, Bilir EK, Fan X, Grierson I, Choudhary A.

Exp Eye Res. 2019 Oct 4:107820. doi: 10.1016/j.exer.2019.107820. [Epub ahead of print]

PMID:
31589839
2.

Investors keep the faith in cancer liquid biopsies.

Sheridan C.

Nat Biotechnol. 2019 Sep;37(9):972-974. doi: 10.1038/d41587-019-00022-7. No abstract available.

PMID:
31485041
3.

Inequalities in Exposure to Nitrogen Dioxide in Parks and Playgrounds in Greater London.

Sheridan CE, Roscoe CJ, Gulliver J, de Preux L, Fecht D.

Int J Environ Res Public Health. 2019 Sep 1;16(17). pii: E3194. doi: 10.3390/ijerph16173194.

4.

Pancreatic cancer provides testbed for first mechanotherapeutics.

Sheridan C.

Nat Biotechnol. 2019 Aug;37(8):829-831. doi: 10.1038/d41587-019-00019-2. No abstract available.

PMID:
31375797
5.

Somatic mutations and cell identity linked by Genotyping of Transcriptomes.

Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND, Alonso A, Sheridan C, Mariani M, Dai X, Harrington E, Pastore A, Cubillos-Ruiz JR, Tam W, Hoffman R, Rabadan R, Scandura JM, Abdel-Wahab O, Smibert P, Landau DA.

Nature. 2019 Jul;571(7765):355-360. doi: 10.1038/s41586-019-1367-0. Epub 2019 Jul 3.

PMID:
31270458
6.

Billion-dollar deal propels RNAi to CNS frontier.

Sheridan C.

Nat Biotechnol. 2019 Jun 11. doi: 10.1038/d41587-019-00014-7. [Epub ahead of print] No abstract available.

PMID:
31267098
7.

A Case of Intermittent Exercise-Induced Foot Drop in a Recreational Runner.

Sheridan CJ, Bowditch M.

Clin J Sport Med. 2019 Jun 12. doi: 10.1097/JSM.0000000000000760. [Epub ahead of print]

PMID:
31219929
8.

Nature Biotechnology's academic spinouts of 2018.

Garber K, Landhuis E, Sheridan C, Senior M, DeFrancesco L.

Nat Biotechnol. 2019 Jun;37(6):601-612. doi: 10.1038/s41587-019-0139-6. No abstract available.

PMID:
31133743
9.

Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia.

Gaiti F, Chaligne R, Gu H, Brand RM, Kothen-Hill S, Schulman RC, Grigorev K, Risso D, Kim KT, Pastore A, Huang KY, Alonso A, Sheridan C, Omans ND, Biederstedt E, Clement K, Wang L, Felsenfeld JA, Bhavsar EB, Aryee MJ, Allan JN, Furman R, Gnirke A, Wu CJ, Meissner A, Landau DA.

Nature. 2019 May;569(7757):576-580. doi: 10.1038/s41586-019-1198-z. Epub 2019 May 15.

PMID:
31092926
10.

Unicorn startup trawls databases for protective genetic modifiers.

Sheridan C.

Nat Biotechnol. 2019 Apr 5. doi: 10.1038/d41587-019-00010-x. [Epub ahead of print] No abstract available.

PMID:
31053810
11.

The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight.

Garrett-Bakelman FE, Darshi M, Green SJ, Gur RC, Lin L, Macias BR, McKenna MJ, Meydan C, Mishra T, Nasrini J, Piening BD, Rizzardi LF, Sharma K, Siamwala JH, Taylor L, Vitaterna MH, Afkarian M, Afshinnekoo E, Ahadi S, Ambati A, Arya M, Bezdan D, Callahan CM, Chen S, Choi AMK, Chlipala GE, Contrepois K, Covington M, Crucian BE, De Vivo I, Dinges DF, Ebert DJ, Feinberg JI, Gandara JA, George KA, Goutsias J, Grills GS, Hargens AR, Heer M, Hillary RP, Hoofnagle AN, Hook VYH, Jenkinson G, Jiang P, Keshavarzian A, Laurie SS, Lee-McMullen B, Lumpkins SB, MacKay M, Maienschein-Cline MG, Melnick AM, Moore TM, Nakahira K, Patel HH, Pietrzyk R, Rao V, Saito R, Salins DN, Schilling JM, Sears DD, Sheridan CK, Stenger MB, Tryggvadottir R, Urban AE, Vaisar T, Van Espen B, Zhang J, Ziegler MG, Zwart SR, Charles JB, Kundrot CE, Scott GBI, Bailey SM, Basner M, Feinberg AP, Lee SMC, Mason CE, Mignot E, Rana BK, Smith SM, Snyder MP, Turek FW.

Science. 2019 Apr 12;364(6436). pii: eaau8650. doi: 10.1126/science.aau8650.

PMID:
30975860
12.

Llama-inspired antibody fragment approved for rare blood disorder.

Sheridan C.

Nat Biotechnol. 2019 Apr;37(4):333-334. doi: 10.1038/s41587-019-0101-7. No abstract available.

PMID:
30940950
13.

Publisher Correction: Death by inflammation: drug makers chase the master controller.

Sheridan C.

Nat Biotechnol. 2019 Apr;37(4):480. doi: 10.1038/s41587-019-0082-6.

PMID:
30842600
14.

Drug developers switch gears to inhibit STING.

Sheridan C.

Nat Biotechnol. 2019 Mar;37(3):199-201. doi: 10.1038/s41587-019-0060-z. No abstract available.

PMID:
30833772
15.

The role of category density in pigeons' tracking of relevant information.

Sheridan CL, Castro L, Fonseca S, Wasserman EA.

Learn Behav. 2019 Sep;47(3):234-244. doi: 10.3758/s13420-019-00372-x.

PMID:
30719680
16.

Death by inflammation: drug makers chase the master controller.

Sheridan C.

Nat Biotechnol. 2019 Feb;37(2):111-113. doi: 10.1038/s41587-019-0023-4. No abstract available. Erratum in: Nat Biotechnol. 2019 Mar 6;:.

PMID:
30718870
17.

To win at gene therapy, companies pick viruses with production credentials.

Sheridan C.

Nat Biotechnol. 2019 Jan 3;37(1):5-6. doi: 10.1038/nbt0119-5. No abstract available.

PMID:
30605157
18.

The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials.

Sheridan CM, Garcia VE, Ahyong V, DeRisi JL.

Malar J. 2018 Dec 12;17(1):465. doi: 10.1186/s12936-018-2616-7.

19.

Wnt is back in drugmakers' sights, but is it druggable?

Sheridan C.

Nat Biotechnol. 2018 Nov 9;36(11):1028-1029. doi: 10.1038/nbt1118-1028. No abstract available.

PMID:
30412206
20.

Sangamo's landmark genome editing trial gets mixed reception.

Sheridan C.

Nat Biotechnol. 2018 Oct 11;36(10):907-908. doi: 10.1038/nbt1018-907. No abstract available.

PMID:
30307929
21.

Commensal microbiota induces colonic barrier structure and functions that contribute to homeostasis.

Hayes CL, Dong J, Galipeau HJ, Jury J, McCarville J, Huang X, Wang XY, Naidoo A, Anbazhagan AN, Libertucci J, Sheridan C, Dudeja PK, Bowdish DME, Surette MG, Verdu EF.

Sci Rep. 2018 Sep 21;8(1):14184. doi: 10.1038/s41598-018-32366-6.

22.

Hydraulic study of a non-steady horizontal sub-surface flow constructed wetland during start-up.

Aylward L, Bonner R, Sheridan C, Kappelmeyer U.

Sci Total Environ. 2019 Jan 1;646:880-892. doi: 10.1016/j.scitotenv.2018.07.324. Epub 2018 Jul 25.

PMID:
30235647
23.

Roche splashes $2.4 billion on Foundation Medicine's cancer platform.

Sheridan C.

Nat Biotechnol. 2018 Sep 6;36(9):779-780. doi: 10.1038/nbt0918-779. No abstract available.

PMID:
30188548
24.

Differential Distribution of Laminin N-Terminus α31 Across the Ocular Surface: Implications for Corneal Wound Repair.

Barrera V, Troughton LD, Iorio V, Liu S, Oyewole O, Sheridan CM, Hamill KJ.

Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4082-4093. doi: 10.1167/iovs.18-24037. Erratum in: Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4463.

25.

Gene therapy rescues newborns with spinal muscular atrophy.

Sheridan C.

Nat Biotechnol. 2018 Aug 6;36(8):669-670. doi: 10.1038/nbt0818-669. No abstract available.

PMID:
30080825
26.

Merck vaccine heads Ebola countermeasures.

Sheridan C.

Nat Biotechnol. 2018 Jul 6;36(7):563-565. doi: 10.1038/nbt0718-563a. No abstract available.

PMID:
29979662
27.

Can Technology Help Us Find Patients? Identifying Patients for Cancer Registry with the Use of a Software Product.

Sheridan C.

J Registry Manag. 2018 Summer;45(2):72-73. No abstract available.

PMID:
31533130
28.

Mammoth, Arbor and Beam launch new wave of CRISPR startups.

Sheridan C.

Nat Biotechnol. 2018 Jun 6;36(6):479-480. doi: 10.1038/nbt0618-479. No abstract available.

PMID:
29874204
29.

Removal of dissolved chromium from synthetic mine effluent: A mesocosm experiment.

Amin R, Edraki M, Doley D, Sheridan C.

Sci Total Environ. 2018 Oct 1;637-638:1252-1261. doi: 10.1016/j.scitotenv.2018.05.102. Epub 2018 May 22.

PMID:
29801218
30.

The availability of second generation feedstocks for the treatment of acid mine drainage and to improve South Africa's bio-based economy.

Westensee DK, Rumbold K, Harding KG, Sheridan CM, van Dyk LD, Simate GS, Postma F.

Sci Total Environ. 2018 Oct 1;637-638:132-136. doi: 10.1016/j.scitotenv.2018.04.410. Epub 2018 May 8.

PMID:
29751295
31.

Allogene and Celularity move CAR-T therapy off the shelf.

Sheridan C.

Nat Biotechnol. 2018 May 9;36(5):375-377. doi: 10.1038/nbt0518-375. No abstract available.

PMID:
29734306
32.

Low-molecular-weight albumin drug touted for severe osteoarthritis.

Sheridan C.

Nat Biotechnol. 2018 Apr 5;36(4):293. doi: 10.1038/nbt0418-293. No abstract available.

PMID:
29621216
33.

Developing a Model Cancer Registry: The Sarah Cannon Model.

Sheridan C, Etzold N, Reynolds J.

J Registry Manag. 2017 Summer;44(2):87-8. No abstract available.

PMID:
29611903
34.

First off-the-shelf mesenchymal stem cell therapy nears European approval.

Sheridan C.

Nat Biotechnol. 2018 Mar 6;36(3):212-214. doi: 10.1038/nbt0318-212a. No abstract available.

PMID:
29509727
35.

Drugmakers cling to dual IL-13/IL-4 blockbuster hopes.

Sheridan C.

Nat Biotechnol. 2018 Jan 10;36(1):3-5. doi: 10.1038/nbt0118-3. No abstract available.

PMID:
29319691
36.

Ablynx's nanobody fragments go places antibodies cannot.

Sheridan C.

Nat Biotechnol. 2017 Dec 8;35(12):1115-1117. doi: 10.1038/nbt1217-1115. No abstract available.

PMID:
29220018
37.

With Alnylam's amyloidosis success, RNAi approval hopes soar.

Sheridan C.

Nat Biotechnol. 2017 Nov 9;35(11):995-997. doi: 10.1038/nbt1117-995. No abstract available.

PMID:
29121028
38.

Novartis trial validates inflammasome as chronic disease driver.

Sheridan C.

Nat Biotechnol. 2017 Oct 11;35(10):893-894. doi: 10.1038/nbt1017-893. No abstract available.

PMID:
29020007
39.

CRISPR patent estate splinters.

Sheridan C.

Nat Biotechnol. 2017 Sep 11;35(9):808-809. doi: 10.1038/nbt0917-808b. No abstract available. Erratum in: Nat Biotechnol. 2017 Dec 8;35(12 ):1124.

PMID:
28898216
40.

Erratum: Nature Biotechnology's academic spinouts of 2016.

Bouchie A, DeFrancesco L, Sheridan C, Webb S.

Nat Biotechnol. 2017 Aug 8;35(8):797. doi: 10.1038/nbt0817-797b. No abstract available.

PMID:
28787418
41.

First new drug approval for AML in 15 years.

Sheridan C.

Nat Biotechnol. 2017 Aug 8;35(8):696-698. doi: 10.1038/nbt0817-696. No abstract available.

PMID:
28787411
42.

First approval in sight for Novartis' CAR-T therapy after panel vote.

Sheridan C.

Nat Biotechnol. 2017 Aug 8;35(8):691-693. doi: 10.1038/nbt0817-691. No abstract available.

PMID:
28787408
43.

The formation of a functional retinal pigment epithelium occurs on porous polytetrafluoroethylene substrates independently of the surface chemistry.

Kearns VR, Tasker J, Zhuola, Akhtar R, Bachhuka A, Vasilev K, Sheridan CM, Williams RL.

J Mater Sci Mater Med. 2017 Aug;28(8):124. doi: 10.1007/s10856-017-5926-3. Epub 2017 Jul 13.

44.

Interest rekindles in drug cocktails that reprogram cells.

Sheridan C.

Nat Biotechnol. 2017 Jun 7;35(6):489-490. doi: 10.1038/nbt0617-489. No abstract available.

PMID:
28591109
45.

RPE65 and the Accumulation of Retinyl Esters in Mouse Retinal Pigment Epithelium.

Sheridan C, Boyer NP, Crouch RK, Koutalos Y.

Photochem Photobiol. 2017 May;93(3):844-848. doi: 10.1111/php.12738.

46.

Genentech's Ocrevus heralds new chapter in MS treatment.

Sheridan C.

Nat Biotechnol. 2017 May 9;35(5):393-394. doi: 10.1038/nbt0517-393. No abstract available.

PMID:
28486459
47.

Nature Biotechnology's academic spinouts of 2016.

Bouchie A, DeFrancesco L, Sheridan C, Webb S.

Nat Biotechnol. 2017 Apr 11;35(4):322-333. doi: 10.1038/nbt.3847. No abstract available.

PMID:
28398323
48.

National Academies relax stance on germline edits.

Sheridan C.

Nat Biotechnol. 2017 Apr 11;35(4):295-296. doi: 10.1038/nbt0417-295. No abstract available.

PMID:
28398320
49.

Celgene eyes 'inverse vaccines' in Anokion and Delinia deals.

Sheridan C.

Nat Biotechnol. 2017 Mar 7;35(3):189-190. doi: 10.1038/nbt0317-189a. No abstract available.

PMID:
28267723
50.

Grail to pour $1 billion into blood test to detect early cancer.

Sheridan C.

Nat Biotechnol. 2017 Feb 8;35(2):101-102. doi: 10.1038/nbt0217-101. No abstract available.

PMID:
28178244

Supplemental Content

Loading ...
Support Center